Quris is a technology company.
Quris has raised $28.0M across 2 funding rounds.
Quris has raised $28.0M in total across 2 funding rounds.
Quris (also known as Quris-AI or Quris Technologies LTD) is a biotech company developing a Bio-AI platform to predict drug safety and efficacy in humans, addressing the high failure rate of clinical trials (89% of drugs fail).[1][2] It combines machine learning trained on data from miniaturized "patients-on-a-chip" (interconnected organ systems using stem-cell-derived tissues and nano-sensing) to simulate human responses, reducing reliance on animal testing, cutting development costs by hundreds of millions per drug, and accelerating market delivery.[1][2] Based in Boston and Tel Aviv, Quris serves pharmaceutical companies like Merck KGaA, which is testing its platform for liver toxicity risks, and has raised $28 million in seed funding from top investors.[1][2]
The platform tackles a trillion-dollar industry challenge by generating terabytes of data for AI classification algorithms, enabling scalable, accurate clinical predictions without prior scalability limitations.[1][2]
Founded in 2019 and headquartered in Tel Aviv (with operations in Boston), Quris emerged from years of ideation by Isaac Bentwich, MD, its Founder & CEO, alongside co-founder Yossi Haran (CTO).[1][2][3][4] Bentwich, a medical doctor, envisioned disrupting drug development's core issue—poor clinical safety prediction—by integrating AI, patient-on-a-chip tech, stem-cell genomics, and real-time nano-sensing.[1] The idea built on pioneers like Moderna co-founder Prof. Robert Langer and Nobel Laureate Prof. Aaron Ciechanover, who lead its advisory board, drawing from their expertise in machine learning, big data, genomics, medtech, and medical devices.[2][3]
Early traction accelerated in 2022 with fast-tracked R&D, team expansion, and key partnerships, including a multi-year deal with Merck KGaA; this followed $28 million in seed funding.[1][2]
Quris stands out in AI-pharma through these key strengths:
Quris rides the AI-biopharma convergence trend, amplified by post-2020 advances in machine learning, stem cells, and organoids, at a time when drug development's $2.6 billion average cost and 90%+ attrition demand innovation.[1][2] Timing aligns with regulatory shifts favoring human-relevant models (e.g., FDA's organ-chip interest) and ESG pressures to cut animal testing, while big pharma seeks AI to derisk pipelines amid talent shortages.[1][2]
It influences the ecosystem by partnering with giants like Merck, validating Bio-AI for mainstream adoption, and inspiring hybrids of hardware (chips), biology, and software—potentially slashing industry failures and enabling faster therapies for unmet needs like longevity drugs.[1][2][3]
Quris is poised for explosive growth as AI-pharma hits an "inflection point," with expanded Merck collaboration and platform scaling likely driving Series A funding and more deals.[1][2] Trends like multimodal AI, advanced organ-chips, and real-world evidence integration will sharpen its edge, while biopharma's AI investment surge (projected billions) fuels adoption. Its influence could evolve from niche predictor to industry standard, redefining drug development much like AlphaFold did protein folding—ultimately delivering safer drugs faster to patients.[1][2] This Bio-AI pioneer is set to transform a trillion-dollar bottleneck into opportunity.
Quris has raised $28.0M in total across 2 funding rounds.
Quris's investors include iAngels, NEVA SGR, Welltech Ventures.
Quris has raised $28.0M across 2 funding rounds. Most recently, it raised $19.0M Seed in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $19.0M Seed | iAngels, NEVA SGR, Welltech Ventures | |
| Oct 1, 2021 | $9.0M Seed | iAngels, Welltech Ventures, NEVA SGR |